Wednesday, October 25, 2023
Abbott has released new data from recent research presentations demonstrating the positive outcomes achieved by its minimally invasive cardiac devices in the treatment of mitral and tricuspid valve conditions. These findings include results from the TRILUMINATE™ pivotal trial, which underscore the safety and effectiveness of the TriClip™ transcatheter edge-to-edge repair (TEER) system in addressing severe tricuspid regurgitation (TR) in symptomatic patients, even when optimal medical therapy has been attempted. Additionally, the company has presented fresh data from the MitraClip™ EXPAND G4 real-world registry, highlighting the advantages of this device for a diverse range of patients with mitral regurgitation (MR).
Mitral and tricuspid valve issues in individuals with MR and TR can impair blood circulation and place excessive strain on the heart, leading to other cardiovascular complications and a diminished quality of life. In the past, surgical intervention was often the primary approach for MR and TR. However, Abbott's portfolio of minimally invasive structural heart devices has significantly expanded treatment options, offering effective solutions with reduced surgical risks for patients across the globe.
The TRILUMINATE pivotal trial represents the world's first controlled clinical study of its kind, assessing the safety and effectiveness of transcatheter repair with the TriClip system in severe TR cases in comparison to standard medical therapy. On the other hand, the EXPAND G4 study is a global, multi-center real-world study involving more than 1,100 patients. This study reaffirms the safety and efficacy of the MitraClip G4 system across a wide spectrum of anatomical considerations in patients.
Source: prnewswire.com
